Oxaprozin Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 600 mg
Reference Brands: Daypro (USA)
Category:
Anaesthetics
Oxaprozin is available in Tablets
and strengths such as 600 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Oxaprozin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Oxaprozin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve inflammation, swelling, stiffness, and joint pain associated with osteoarthritis, rheumatoid arthritis, and other inflammatory joint disorders. Chemically, it is classified as a propionic acid derivative, a subgroup of NSAIDs known for effective anti-inflammatory and analgesic activity.
Oxaprozin works by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins responsible for pain and inflammation. Its safety and efficacy have been established in children over 6 years of age with juvenile rheumatoid arthritis, while elderly patients may have an increased risk of adverse reactions and require careful monitoring.
Oxaprozin has been evaluated in clinical trials comparing multiple NSAIDs for the short-term treatment of ankylosing spondylitis (AS). Study results demonstrated that oxaprozin significantly reduced pain compared to placebo and was associated with fewer adverse effects than some commonly used NSAIDs such as naproxen.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing